Can neoadjuvant systemic therapy provide additional benefits for T1 HER2+ breast cancer patients: a subgroup analysis based on different high-risk signatures

CONCLUSION: Our findings suggest that NAST does not provide additional benefit to patients with T1 HER2+ breast cancer, even in the presence of lymph node metastasis, T1c, or hormone receptor negativity. This study facilitates the implementation of individualized management strategies.PMID:38592638 | DOI:10.1007/s12094-024-03472-x

Source: Clinical Breast Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Lidan Chang Dandan Liu Xuyan Zhao Luyao Dai Xueting Ren Qian Hao Peinan Liu Hao Wu Xiaobin Ma Huafeng Kang Source Type: research